Catalyst Pharma to Attend BofA Health Care Conference 2024

CORAL GABLES, Fla., May 01, 2024 -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a biopharmaceutical firm at the commercial stage focusing on in-licensing, developing, and marketing novel treatments for patients with rare, challenging diseases, has announced its upcoming participation in the BofA Securities Health Care Conference 2024. The conference is set to take place on Tuesday, May 14, 2024, at the Encore Hotel in Las Vegas, Nevada. 

The company's President and CEO, Richard J. Daly, along with other members of the Catalyst management team, will be presenting at the conference. Their presentation is scheduled for 5:00 pm PT on that day. Interested parties will be able to access a live webcast of the presentation through the Investors section of the Catalyst website. Additionally, a replay of the webcast will be accessible for at least 14 days following the event.

Catalyst Pharmaceuticals, Inc. is dedicated to the development and commercialization of pioneering medicines aimed at treating rare and hard-to-treat conditions. The company's flagship product in the U.S. market, FIRDAPSE® (amifampridine) Tablets 10 mg, has received approval for treating Lambert-Eaton myasthenic syndrome (LEMS) in adults and children aged six to seventeen.

In January 2023, Catalyst expanded its portfolio by acquiring U.S. commercial rights to FYCOMPA® (perampanel) CIII. This prescription medication is approved for treating epilepsy in individuals aged four and older. It can be used alone or alongside other medications to treat partial-onset seizures, both with and without secondarily generalized seizures, and primary generalized tonic-clonic seizures in those aged 12 and above.

Catalyst's international reach is also significant. Health Canada has approved the use of FIRDAPSE for treating adult LEMS patients in Canada. Moreover, on July 18, 2023, Catalyst secured an exclusive North American license for AGAMREE® (vamorolone) oral suspension 40 mg/mL. AGAMREE is a novel corticosteroid treatment for Duchenne Muscular Dystrophy and has received FDA Orphan Drug and Fast Track designations. The FDA approved AGAMREE for commercialization in the U.S. on October 26, 2023, and it became available by prescription on March 13, 2024.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!